About This Show
ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.
The journal is published by BMJ on behalf of ESMO.
http://esmoopen.bmj.com/Read more »
Most Recent Episode
Questions asked in everyday practice: Immune Checkpoint Inhibitors
Immunotherapy has been approved for several indications in Oncology, resulting in an increasing number of physicians that use it to treat their patients. In this podcast, Teresa Amaral, member of the ESMO YOC, interviews Professor John Haanen (Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology; Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, the Netherlands) on the topic: “Questions asked in everyday practice: Immune Checkpoint Inhibitors”. Currently, there is no consensus about how long should we treat patients with immunotherapy and the optimal duration might also be different considering the tumor type (e.g. melanoma, NSCLC). In some patients, stopping early due to adverse events doesn’t seem to be detrimental, but the follow-up time is still short to make definitive assumptions. When treating a patient with a previous autoimmune disease, several aspects need to be considered, namely, which type of immunosuppression is the patient receiving now, in which dosage and how long has the autoimmune disease been stable. Patients that received a solid organ transplant pose an extra challenge. For patients that develop grade 4 autoimmune adverse events, re-treatment with immunotherapy should be extensively discussed. In case of severe autoimmune toxicity that does not respond to the treatments referred in the guidelines, and if the treating physician is not experienced with escalating immunosuppressive therapy, consultation with other centers with more familiarity and expertise on this topic should be considered.Read more »
Episodes of This Show
Sep 5, 2017
Jul 26, 2017